Illumina and Celgene could exit genome researcher Human Longevity in a reverse merger while Openly raised $75m from investors including Advance Venture Partners and Gradient Ventures.

Public markets US-based genome researcher Human Longevity has signed a letter of intent to execute a reverse merger with special purpose acquisition company Freedom Acquisition 1. The non-binding deal would involve the combined business taking Freedom Acquisition 1’s listing on the New York Stock Exchange and would come after $330m in funding from investors including…

The rest of this content is only accessible to Global Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.

Roshini Bains

Roshini Bains is the junior news reporter for Global Corporate Venturing and Global University Venturing.